TSE:4503Pharmaceuticals
Astellas Pharma (TSE:4503) Is Up 6.0% After Q1 Profit Surge Signals Improved Operational Efficiency
Astellas Pharma Inc. has reported past first-quarter 2026 results, with sales rising to ¥640,914 million and net income reaching ¥141,828 million, alongside higher basic and diluted earnings per share from continuing operations versus a year earlier.
The sharp year-on-year jump in net income and earnings per share suggests stronger operational efficiency and profitability than in the prior period.
We’ll now examine how this strong first-quarter profit expansion reshapes Astellas Pharma’s...